title: An unusual presentation of nonarteritic ischemic optic neuropathy with subretinal fluid treated with intravitreal bevacizumab.
abstract: A 62-year-old hypertensive male presented with acute nonarteritic ischemic optic neuropathy (NAION) with contiguous macular edema and subretinal fluid in the right eye. Presenting vision was 20/1000. The patient was treated with intravitreal bevacizumab 1.25 mg/0.05 ml. At 1 month follow-up, the macular edema and the optic nerve head edema completely resolved with a good visual improvement up to 20/40. The visual improvement was maintained at the last follow-up 6 months postinjection. Intravitreal bevacizumab may be a good option for acute NAION especially in an unusual presentation with macular edema and subretinal fluid.
authors.affiliation: Vitreoretina Services, Netra Mandir Eye Institute, Mumbai, Maharashtra, India.
authors.forename: Vivek Pravin
authors.initials: VP
authors.lastname: Dave
authors.forename: Rajeev R
authors.initials: RR
authors.lastname: Pappuru
mesh_terms: D000208:Acute Disease; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001167:Arteritis / Q000175:diagnosis / Q000188:drug therapy; D000068258:Bevacizumab / Q000627:therapeutic use*; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D018917:Optic Neuropathy, Ischemic / Q000175:diagnosis* / Q000188:drug therapy; D058471:Subretinal Fluid; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D058609:Visual Field Tests
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab